Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Treatment strategies for high-risk MM

Jesús San Miguel • 7 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies Bortezomib CAR-T Carfilzomib CC-93269 Daratumumab Isatuximab Lenalidomide Melphalan

Jesus San Miguel, MD, Universidad de Navarra, Navarra, discusses treatment strategies for high-risk multiple myeloma patients, including immunotherapeutic options, such as monoclonal antibodies, bispecific antibodies and CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jesús San Miguel

Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023
1:11
The future of myeloma therapy and where the treatment landscape is moving
Jesús San Miguel • 13 May 2022
1:21
The value of sustained MRD negativity in MM
Jesús San Miguel • 13 May 2022
1:21
MRD evaluation: how, when and for which goal?
Jesús San Miguel • 13 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals